Showing 5371-5380 of 8588 results for "".
- Web‐Based Supply Chain Management Software Launchedhttps://practicaldermatology.com/news/20130418-webbased_supply_chain_management_software_launched/2459562/Aesyntix Health, Inc. launched the Aesyntix Inventory Management (AIM), a web‐based inventory and automated ordering system to enhance its dermatology supply chain management platform. Specifically for dermatology inventory management, AIM helps
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Rosacea Hinders Social Experiences For More Than 16 Million Americanshttps://practicaldermatology.com/news/20130409-rosacea_hinders_social_experiences_for_more_than_16_million_americans/2459570/Roughly half of rosacea patients refuse certain foods and drinks for fear of triggering a rosacea flare-up. That's according to numbers from the National Rosacea Society (NRS), which designated the month of April as Rosacea Awareness Month to alert the public to the early warning signs of rosacea. T
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- Dr. Amy Forman Taub Partners With Mott 50https://practicaldermatology.com/news/20130408-dr_amy_forman_taub_partners_with_mott_50/2459572/Chicago-area board-certified dermatologist Amy Forman Taub, MD teamed up with Mott 50 to create a specially designed sun-protective shirt to be sold at her SKINFO Specialty Skincare Boutique. The breathable, long-sleeve navy Skin For Life shirt is pump
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surge
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for